Cypralis
Cypralis is a biotechnology company focused on discovering and developing novel medicines for acute and chronic degenerative diseases. It specializes in targeting peptidyl-prolyl isomerases (PPIases), a family of druggable protein targets involved in many diseases. The company has a strong pipeline of cyclophilin inhibitors and collaborates with various research institutions and pharmaceutical companies to advance its therapeutics.
Industries
Nr. of Employees
medium (51-250)
Cypralis
St John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK
Patents
Products
Cyclophilin inhibitor candidate for acute kidney injury (early clinical)
A small-molecule cyclophilin inhibitor advanced into Phase 1 clinical testing for prevention/treatment of acute kidney injury associated with major surgery and intended for perioperative renal protection.
Preclinical cyclophilin D inhibitor candidate for acute pancreatitis
Preclinical cyclophilin D inhibitor series demonstrating protection of pancreatic cells and efficacy in mouse models of acute pancreatitis; advanced toward IND/CTA enabling studies.
Library of cyclophilin inhibitor compounds and associated patent estate
A large, structurally diverse collection of over 1,800–2,000 rationally designed cyclophilin inhibitor compounds with associated patent filings available to support discovery and licensing.
Cyclophilin inhibitor candidate for acute kidney injury (early clinical)
A small-molecule cyclophilin inhibitor advanced into Phase 1 clinical testing for prevention/treatment of acute kidney injury associated with major surgery and intended for perioperative renal protection.
Preclinical cyclophilin D inhibitor candidate for acute pancreatitis
Preclinical cyclophilin D inhibitor series demonstrating protection of pancreatic cells and efficacy in mouse models of acute pancreatitis; advanced toward IND/CTA enabling studies.
Library of cyclophilin inhibitor compounds and associated patent estate
A large, structurally diverse collection of over 1,800–2,000 rationally designed cyclophilin inhibitor compounds with associated patent filings available to support discovery and licensing.
Services
Collaborative research and licensing arrangements with pharmaceutical companies, academic institutions and regional partners to discover and develop cyclophilin inhibitor candidates.
Preclinical pharmacology, chemistry and ADME/DMPK programs designed to advance candidates through IND/CTA enabling studies and into early clinical trials.
Collaborative research and licensing arrangements with pharmaceutical companies, academic institutions and regional partners to discover and develop cyclophilin inhibitor candidates.
Preclinical pharmacology, chemistry and ADME/DMPK programs designed to advance candidates through IND/CTA enabling studies and into early clinical trials.
Expertise Areas
- Cyclophilin (PPIase) inhibitor drug discovery
- Small-molecule medicinal chemistry and macrocycle design
- Preclinical pharmacology and in vivo disease models
- Lead optimisation and ADME/DMPK
Key Technologies
- Structure-based drug design
- Macrocyclic small-molecule synthesis
- Biochemical PPIase/cyclophilin screening assays
- Cell-based in vitro assays (human and murine pancreatic acinar cells)
News & Updates
Cypralis CEO, Simon Kerr, presented to investors and biotech professionals at the Biotech and Money World Congress, discussing future investment plans and research strategies.
Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive rights to develop and commercialize certain macrocyclic inhibitors of peptide bond isomerases, excluding oncology and virology.
Cypralis, in collaboration with the University of Liverpool, will present in-vitro and in-vivo data on CC-1233, a potent inhibitor of cyclophilin D, in models of acute pancreatitis.
Cypralis received funding from Innovate UK to discover new dual-activity inhibitors of cell death and fibrosis for the treatment of Chronic Pancreatitis and other fibrotic diseases.
Cypralis was awarded $524,000 by the ADDF to develop selective cyclophilin D inhibitors for neurodegenerative diseases such as Alzheimer’s.
A publication in the Journal of Medicinal Chemistry describes the discovery of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent activity against HCV, based on natural product sanglifehrin A.
Cypralis CEO, Simon Kerr, presented to investors and biotech professionals at the Biotech and Money World Congress, discussing future investment plans and research strategies.
Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive rights to develop and commercialize certain macrocyclic inhibitors of peptide bond isomerases, excluding oncology and virology.
Cypralis, in collaboration with the University of Liverpool, will present in-vitro and in-vivo data on CC-1233, a potent inhibitor of cyclophilin D, in models of acute pancreatitis.
Cypralis received funding from Innovate UK to discover new dual-activity inhibitors of cell death and fibrosis for the treatment of Chronic Pancreatitis and other fibrotic diseases.
Cypralis was awarded $524,000 by the ADDF to develop selective cyclophilin D inhibitors for neurodegenerative diseases such as Alzheimer’s.
A publication in the Journal of Medicinal Chemistry describes the discovery of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent activity against HCV, based on natural product sanglifehrin A.